Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING Phase 3

Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery

NCT03757949 · View on ClinicalTrials.gov ↗

Study Summary

This phase III trial studies how well nutrition therapy works in improving immune system in patients with bladder cancer that can be removed by surgery. Improving nutrition before and after surgery may reduce the infections and other problems that sometimes occur after surgery.

Conditions Studied

Interventions

  • OTHER Quality-of-Life Assessment
  • OTHER Laboratory Biomarker Analysis
  • OTHER Questionnaire Administration
  • DIETARY_SUPPLEMENT Nutritional Intervention
  • OTHER Placebo Administration

Study Locations (20)

California

  • City of Hope Comprehensive Cancer Center — Duarte
  • Los Angeles County-USC Medical Center — Los Angeles
  • USC / Norris Comprehensive Cancer Center — Los Angeles
  • USC Norris Oncology/Hematology-Newport Beach — Newport Beach
  • Keck Medical Center of USC Pasadena — Pasadena

Kansas

  • University of Kansas Clinical Research Center — Fairway
  • University of Kansas Cancer Center — Kansas City
  • University of Kansas Hospital-Indian Creek Campus — Overland Park
  • University of Kansas Hospital-Westwood Cancer Center — Westwood

Illinois

  • Northwestern University — Chicago
  • Cancer Care Specialists of Illinois - Decatur — Decatur
  • Decatur Memorial Hospital — Decatur

Michigan

  • Saint Joseph Mercy Hospital — Ann Arbor
  • IHA Hematology Oncology Consultants-Brighton — Brighton
  • Saint Joseph Mercy Brighton — Brighton

Maine

  • Maine Medical Center-Bramhall Campus — Portland
  • Maine Medical Center- Scarborough Campus — Scarborough

Colorado

  • University of Colorado Hospital — Aurora

Florida

  • Mayo Clinic in Florida — Jacksonville

Louisiana

  • LSU Healthcare Network / Metairie Multi-Specialty Clinic — Metairie

Trial Details

FieldValue
Enrollment Target 203 participants
Start Date 2019-03-05
Est. Completion 2027-01-01
Phase Phase 3

Sponsor

SWOG Cancer Research Network

212 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03757949

The ClinicalTrials.gov registry entry for NCT03757949 describes a study currently listed as active not recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 203 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 212 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Bladder Carcinoma appearing as the primary indexed condition, and to 5 interventions — of which Quality-of-Life Assessment is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03757949 reports 20 study locations spanning 8 distinct geographic areas — top geographies include California, Kansas, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03757949 about?

NCT03757949 is a clinical study titled "Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery". This phase III trial studies how well nutrition therapy works in improving immune system in patients with bladder cancer that can be removed by surgery. Improving nutrition before and after surgery may reduce the infections and other problems that sometimes occur after surgery.

What is the current status of trial NCT03757949?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 203 participants. The study started on 2019-03-05. Estimated completion is 2027-01-01.

What conditions does trial NCT03757949 study?

This clinical trial studies the following conditions: Bladder Carcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03757949?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), Nutritional Intervention (DIETARY_SUPPLEMENT), Placebo Administration (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03757949?

This trial is sponsored by SWOG Cancer Research Network, which has 212 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03757949 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial